FDA nod for Gilead to expand hepatitis drug to six years or older patients
HQ Team March 28, 2024: US regulator, the FDA has approved Gilead Sciences, Inc.’s supplemental new drug application for treating chronic hepatitis B.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 28, 2024: US regulator, the FDA has approved Gilead Sciences, Inc.’s supplemental new drug application for treating chronic hepatitis B.
HQ Team February 8, 2024: Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US.
HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.
The number of people affected by neglected tropical diseases (NTDs) has fallen by 80 million between 2020 and 2021, a WHO report stated.